Novartis Inc header image

Novartis Inc

NOVN

Equity

ISIN CH0012005267 / Valor 1200526

SIX Swiss Exchange (2026-03-25)

CHF 119.62+1.17%

Novartis Inc
UMushroom community rating:

4.06 45 votes No rating yet

NegativeNeutralPositive

About company

Novartis Inc. is a global healthcare company that specializes in the development and distribution of innovative medicines. With a focus on addressing unmet medical needs, Novartis aims to improve and extend the lives of people suffering from serious diseases. The company operates in several core therapeutic areas, including cardiovascular, renal and metabolic diseases, immunology, neuroscience, and oncology. Novartis is known for its commitment to research and development, leveraging advanced technology platforms to create groundbreaking therapies. With a workforce of approximately 78,000 employees representing over 140 nationalities, Novartis has a significant global presence, reaching more than 284 million patients worldwide. The company's strategy revolves around delivering high-value medicines and employing novel access approaches to alleviate some of society's most significant disease burdens.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

19.7%1Y

62.3%3Y

53.8%5Y

Performance

21.3%1Y

18.9%3Y

17.9%5Y

Volatility

284209 M

Market cap (USD)

3,374,558

Daily traded volume (Shares)

88.82 / 87.81

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.06

45 votes

Performance:

3.75

Innovation:

4.00

Society:

4.01

Nature:

3.53

Oliver Frei

Switzerland, 21 Mar 2026

-

Pavle Stojicic

Switzerland, 20 Mar 2026

Great company, wrong year to expect excitement. Own it in 2027 when the patent cliff is behind them and the new drugs are fully ramping.

Lorenzo Castillejo

Switzerland, 19 Mar 2026

Amazing stock

EQUITIES OF THE SAME SECTOR

National Healthcare Corp

National Healthcare Corp Valor: 836282

Annual Return

-50%0%+50%

Risk level

110

0.15%USD 161.99

Dexcom Inc

Dexcom Inc Valor: 2107726

Annual Return

-50%0%+50%

Risk level

110

1.00%USD 66.60

Insulet Corp

Insulet Corp Valor: 2941247

Annual Return

-50%0%+50%

Risk level

110

-0.70%USD 225.50

Henry Schein Inc

Henry Schein Inc Valor: 83527

Annual Return

-50%0%+50%

Risk level

110

-0.59%USD 74.02

NovoCure Limited

NovoCure Limited Valor: 29570025

Annual Return

-50%0%+50%

Risk level

110

-3.89%USD 11.36

Roivant Sciences Limited

Roivant Sciences Limited Valor: 113331044

Annual Return

-50%0%+50%

Risk level

110

-3.80%USD 26.87

Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Corp Valor: 912247

Annual Return

-50%0%+50%

Risk level

110

1.17%USD 9.54

ICU Medical Inc

ICU Medical Inc Valor: 940704

Annual Return

-50%0%+50%

Risk level

110

-0.41%USD 129.40

CRISPR Therapeutics Ltd

CRISPR Therapeutics Ltd Valor: 33408113

Annual Return

-50%0%+50%

Risk level

110

-0.96%USD 46.43

Merit Medical Systems Inc

Merit Medical Systems Inc Valor: 951136

Annual Return

-50%0%+50%

Risk level

110

-0.85%USD 67.55

SIX

FactSet

Clearbit

Logos provided by Clearbit